Cost-effectiveness of clobazam as an adjunctive treatment for refractory epilepsy in China

Shunan Chen,Fengqian Mao,Yani Hu,Suhong Wang,Jie Chen,Jiali Zhang,Lingyan Yu,Haibin Dai
DOI: https://doi.org/10.1007/s11096-024-01838-3
IF: 2.305
2024-12-03
International Journal of Clinical Pharmacy
Abstract:Clobazam (CLB) is an effective, safe and well-tolerated adjunctive treatment for refractory epilepsy. However, the cost-effectiveness of CLB in China remains unclear.
pharmacology & pharmacy
What problem does this paper attempt to address?